GlassScriptPhysician profile
Sadat Rashid
NPI 1578728366
$7,496.94
in general payments reported to CMS, 2019-2025
34 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $497 · 2021: $778 · 2022: $1,529 · 2023: $598 · 2024: $1,594 · 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Travel and Lodging: $1,397 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.44 |
| Travel and Lodging | $1,396.92 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,288.67 | 2024-2025 | Axios, General - Therapies, Apollo Esg System |
| Abbvie INC. | $1,742.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $491.94 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $471.44 | 2020-2024 | Stelara, Remicade, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.47 | 2019-2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $294.90 | 2020-2023 | |
| Gilead Sciences, INC. | $235.25 | 2019-2025 | |
| Pfizer INC. | $233.73 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $226.37 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $122.56 | 2025 | Zepbound |
| Olympus America INC. | $120.41 | 2022 | |
| Genzyme Corporation | $103.98 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $103.86 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $82.13 | 2019-2024 | Clenpiq, Rebyota |
| Shionogi INC | $71.37 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Redhill Biopharma INC. | $59.70 | 2021-2022 | |
| Olympus Corporation of The Americas | $53.74 | 2019 | |
| Ironwood Pharmaceuticals, INC | $45.32 | 2020 | |
| Allergan, INC. | $39.85 | 2019-2020 | |
| Braintree Laboratories, INC. | $39.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.20 | 2023 | Cyltezo |
| Celgene Corporation | $34.06 | 2022 | |
| Merck Sharp & Dohme LLC | $32.26 | 2019 | |
| Qol Medical, LLC | $26.04 | 2022 | |
| Ambu INC. | $25.07 | 2020 | |
| Aimmune Therapeutics, INC. | $24.26 | 2024 | |
| Madrigal Pharmaceuticals | $20.26 | 2024 | Resmetirom |
| Ethicon US, LLC | $18.35 | 2022 | |
| Shire North American Group INC | $16.05 | 2019 | |
| Novo Nordisk INC | $15.30 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.87 | 2022 | |
| Eisai INC. | $14.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadat Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.